Cell division during the early stage of embryo development is a trade-off between speed and accuracy; the cells need to ...

Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important ...

Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the ...

Dendritic cells (DCs) have emerged in the field of cancer immunotherapy as the most potent professional antigen-presenting ...

Pancreatic cancer can remain quiet for years, developing undetected before causing symptoms that lead to a diagnosis. Even ...

Can WuXi AppTec’s Integrated Discovery Platform Power Oncology? WuXi AppTec’s integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.

Promatix Biosciences, which was founded in 2020, says the scarcity of truly tumour-selective targets is putting the brakes on ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

Recognizing this individuality has driven scientists to research beyond a one-size-fits-all approach to cancer treatment.

Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by ...

CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 ...

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...